Drug Profile


Alternative Names: CR 1505; Loside; Loxizin

Latest Information Update: 20 Feb 2006

Price : $50

At a glance

  • Originator Rottapharm
  • Developer Kaken Pharmaceutical; Rottapharm
  • Class Anti-inflammatories; Antineoplastics; Basic amino acids; Gastrokinetics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Cholecystokinin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Biliary pain; Pancreatic cancer
  • Discontinued Irritable bowel syndrome; Non-ulcer dyspepsia; Pancreatitis

Most Recent Events

  • 20 Feb 2006 No development reported - Clinical-Phase-Unknown for Biliary pain in Italy (unspecified route)
  • 06 Nov 2003 Discontinued - Preregistration for Pancreatitis in Japan (IV)
  • 06 Nov 2003 Discontinued - Phase-III for Pancreatitis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top